Mylan Rebate Suit

MANHATTAN – A federal court in New York granted class certification in a stockholder suit against pharmaceutical company Mylan accusing it of misclassifying its EpiPen as a generic drug and underpaying federal Medicaid rebates.

%d bloggers like this: